FINWIRES · TerminalLIVE
FINWIRES

HSBC Cuts Dallah Healthcare PT, Keeps at Reduce

By

HSBC on Tuesday lowered the price target for healthcare company Dallah Healthcare (SASE:4004) to 92 Saudi riyals from 116 riyals, while keeping its reduce rating.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

BM Pekao Upgrades Orlen to Buy Rating, Boosts PT

BM Pekao on Wednesday upgraded Poland-based energy group Orlen (PKN.WA) to buy from hold and raised its price target to 166.58 Polish zlotys from 126.16 zlotys.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PKN.WA
Research

RBC Cuts Price Target on Gold Fields to $50 From $68, Keeps Outperform Rating

Gold Fields (GFI) has an average rating of overweight and mean price target of $58.63, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GFI
Research

Well Health Technologies Price Target Raised to $6 at CIBC

CIBC Capital Markets raised its price target on Well Health Technologies (WELL.TO) to $6 from $5.50.Analyst Eric Kyle maintained an Outperformer rating on shares of the Vancouver-based digital health technology company."WELL announced the company has reached its $100 Million annualized adjusted EBITDA target for WELL Canada (Canadian clinics, WELLSTAR, and CYBERWELL) three quarters ahead of plan, in Q2/26 compared to Q1/27 expectations, driven by strong primary care organic growth and two accretive acquisitions," Kyle said in a note to clients."The company acquired an Ontario diagnostics imaging clinic and a Quebec procedural care clinic for $115 Million upfront, generating $22 Million of combined adjusted EBITDA, implying ~5x EBITDA on close," the analyst said."We expect management will increase 2026 guidance when WELL reports Q2 results in August."

$WELL.TO